BACKGROUND: Rapid identification of diverse fusion genes with involvement of PDGFRA or PDGFRB in eosinophilia-associated myeloproliferative neoplasms is essential for adequate clinical management but is complicated by the multitude and heterogeneity of partner genes and breakpoints. DESIGN AND METHODS: We established a generic quantitative reverse transcriptase polymerase chain reaction to detect overexpression of the 3'-regions of PDGFRA or PDGFRB as a possible indicator of an underlying fusion. RESULTS: At diagnosis, all patients with known fusion genes involving PDGFRA (n=5; 51 patients) or PDGFRB (n=5; 7 patients) showed significantly increased normalized expression levels compared to 191 patients with fusion gene-negative eosinophilia or healthy individuals (PDGFRA/ABL: 0.73 versus 0.0066 versus 0.0064, P<0.0001; PDGFRB/ABL: 196 versus 3.8 versus 5.85, P<0.0001). The sensitivity and specificity of the activation screening test were, respectively, 100% and 88.4% for PDGFRA and 100% and 94% for PDGFRB. Furthermore, significant overexpression of PDGFRB was found in a patient with an eosinophilia-associated myeloproliferative neoplasm with uninformative cytogenetics and an excellent response to imatinib. Subsequently, a new SART3-PDGFRB fusion gene was identified by 5'-rapid amplification of cDNA ends polymerase chain reaction (5'-RACE-PCR). CONCLUSIONS: Quantitative reverse transcriptase polymerase chain reaction analysis is a simple and useful adjunct to standard diagnostic assays to detect clinically significant overexpression of PDGFRA and PDGFRB in eosinophilia-associated myeloproliferative neoplasms or related disorders.
BACKGROUND: Rapid identification of diverse fusion genes with involvement of PDGFRA or PDGFRB in eosinophilia-associated myeloproliferative neoplasms is essential for adequate clinical management but is complicated by the multitude and heterogeneity of partner genes and breakpoints. DESIGN AND METHODS: We established a generic quantitative reverse transcriptase polymerase chain reaction to detect overexpression of the 3'-regions of PDGFRA or PDGFRB as a possible indicator of an underlying fusion. RESULTS: At diagnosis, all patients with known fusion genes involving PDGFRA (n=5; 51 patients) or PDGFRB (n=5; 7 patients) showed significantly increased normalized expression levels compared to 191 patients with fusion gene-negative eosinophilia or healthy individuals (PDGFRA/ABL: 0.73 versus 0.0066 versus 0.0064, P<0.0001; PDGFRB/ABL: 196 versus 3.8 versus 5.85, P<0.0001). The sensitivity and specificity of the activation screening test were, respectively, 100% and 88.4% for PDGFRA and 100% and 94% for PDGFRB. Furthermore, significant overexpression of PDGFRB was found in a patient with an eosinophilia-associated myeloproliferative neoplasm with uninformative cytogenetics and an excellent response to imatinib. Subsequently, a new SART3-PDGFRB fusion gene was identified by 5'-rapid amplification of cDNA ends polymerase chain reaction (5'-RACE-PCR). CONCLUSIONS: Quantitative reverse transcriptase polymerase chain reaction analysis is a simple and useful adjunct to standard diagnostic assays to detect clinically significant overexpression of PDGFRA and PDGFRB in eosinophilia-associated myeloproliferative neoplasms or related disorders.
Authors: A Murati; J Adélaïde; V Gelsi-Boyer; A Etienne; V Rémy; H Fezoui; D Sainty; L Xerri; N Vey; S Olschwang; D Birnbaum; M Chaffanet; M J Mozziconacci Journal: Leukemia Date: 2006-06 Impact factor: 11.528
Authors: F Yagasaki; I Jinnai; S Yoshida; Y Yokoyama; A Matsuda; S Kusumoto; H Kobayashi; H Terasaki; K Ohyashiki; N Asou; I Murohashi; M Bessho; K Hirashima Journal: Genes Chromosomes Cancer Date: 1999-11 Impact factor: 5.006
Authors: Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; Francois X Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley Journal: Blood Date: 2006-09-07 Impact factor: 22.113
Authors: Christoph Walz; Georgia Metzgeroth; Claudia Haferlach; Annette Schmitt-Graeff; Alice Fabarius; Volker Hagen; Otto Prümmer; Stefan Rauh; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter Journal: Haematologica Date: 2007-02 Impact factor: 9.941
Authors: Christoph Walz; Claire Curtis; Susanne Schnittger; Beate Schultheis; Georgia Metzgeroth; Claudia Schoch; Eva Lengfelder; Philipp Erben; Martin C Müller; Torsten Haferlach; Andreas Hochhaus; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter Journal: Genes Chromosomes Cancer Date: 2006-10 Impact factor: 5.006
Authors: D M Ross; H K Altamura; C N Hahn; M Nicola; A L Yeoman; M R Holloway; J Geoghegan; J Feng; A W Schreiber; S Branford; S Moore; H S Scott Journal: Leukemia Date: 2015-10-27 Impact factor: 11.528
Authors: M Jawhar; N Naumann; M Knut; J Score; M Ghazzawi; B Schneider; K-A Kreuzer; M Hallek; H G Drexler; J Chacko; L Wallis; A Fabarius; G Metzgeroth; W-K Hofmann; A Chase; W Tapper; A Reiter; N C P Cross Journal: Leukemia Date: 2017-07-28 Impact factor: 11.528
Authors: P Khoury; R Desmond; A Pabon; N Holland-Thomas; J M Ware; D C Arthur; R Kurlander; M P Fay; I Maric; A D Klion Journal: Allergy Date: 2016-03-02 Impact factor: 13.146